Sandy Spring Bank Buys 1,025 Shares of Celgene Corporation (CELG)
Sandy Spring Bank increased its stake in shares of Celgene Corporation (NASDAQ:CELG) by 2.7% during the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 38,685 shares of the biopharmaceutical company’s stock after buying an additional 1,025 shares during the period. Sandy Spring Bank’s holdings in Celgene Corporation were worth $4,814,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Cullinan Associates Inc. raised its stake in shares of Celgene Corporation by 1.5% in the first quarter. Cullinan Associates Inc. now owns 62,318 shares of the biopharmaceutical company’s stock valued at $7,754,000 after buying an additional 900 shares during the last quarter. Oliver Luxxe Assets LLC raised its stake in shares of Celgene Corporation by 208.9% in the first quarter. Oliver Luxxe Assets LLC now owns 12,742 shares of the biopharmaceutical company’s stock valued at $1,585,000 after buying an additional 8,617 shares during the last quarter. Pinnacle Bank acquired a new stake in shares of Celgene Corporation during the first quarter valued at approximately $287,000. Regent Investment Management LLC raised its stake in shares of Celgene Corporation by 11.6% in the first quarter. Regent Investment Management LLC now owns 45,189 shares of the biopharmaceutical company’s stock valued at $5,623,000 after buying an additional 4,685 shares during the last quarter. Finally, Hartwell J M Limited Partnership raised its stake in shares of Celgene Corporation by 32.9% in the first quarter. Hartwell J M Limited Partnership now owns 10,100 shares of the biopharmaceutical company’s stock valued at $1,257,000 after buying an additional 2,500 shares during the last quarter. Institutional investors own 79.43% of the company’s stock.
Shares of Celgene Corporation (NASDAQ CELG) traded up 0.615% during mid-day trading on Friday, hitting $139.785. The stock had a trading volume of 1,911,832 shares. The company has a market cap of $109.36 billion, a PE ratio of 43.290 and a beta of 1.89. The stock has a 50 day moving average price of $133.59 and a 200-day moving average price of $125.91. Celgene Corporation has a 52-week low of $96.93 and a 52-week high of $140.25. Celgene Corporation also was the recipient of some unusual options trading on Thursday. Stock traders acquired 9,159 put options on the stock. This is an increase of 162% compared to the average daily volume of 3,491 put options.
Celgene Corporation (NASDAQ:CELG) last released its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $1.82 earnings per share for the quarter, beating the consensus estimate of $1.61 by $0.21. Celgene Corporation had a return on equity of 68.51% and a net margin of 21.35%. The firm had revenue of $3.27 billion during the quarter, compared to the consensus estimate of $3.23 billion. During the same period last year, the business posted $1.44 EPS. Celgene Corporation’s quarterly revenue was up 18.7% on a year-over-year basis. On average, equities analysts expect that Celgene Corporation will post $7.32 earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: “Sandy Spring Bank Buys 1,025 Shares of Celgene Corporation (CELG)” was published by Watch List News and is the property of of Watch List News. If you are accessing this piece on another website, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The original version of this piece can be viewed at https://www.watchlistnews.com/sandy-spring-bank-buys-1025-shares-of-celgene-corporation-celg/1536345.html.
Several analysts have commented on CELG shares. Vetr lowered Celgene Corporation from a “strong-buy” rating to a “buy” rating and set a $146.88 price objective on the stock. in a report on Tuesday. Cantor Fitzgerald reissued a “buy” rating on shares of Celgene Corporation in a report on Monday. BTIG Research reissued a “buy” rating and issued a $138.00 price objective on shares of Celgene Corporation in a report on Wednesday, May 24th. Argus raised Celgene Corporation from a “hold” rating to a “buy” rating and raised their price objective for the company from $96.93 to $160.00 in a report on Monday, July 31st. Finally, Jefferies Group LLC reissued a “buy” rating and issued a $160.00 price objective on shares of Celgene Corporation in a report on Tuesday, July 11th. One analyst has rated the stock with a sell rating, six have issued a hold rating and twenty-three have given a buy rating to the company. The company has an average rating of “Buy” and an average target price of $147.38.
In related news, Director Michael D. Casey sold 9,250 shares of the firm’s stock in a transaction that occurred on Monday, June 19th. The stock was sold at an average price of $125.59, for a total value of $1,161,707.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Rupert Vessey sold 4,785 shares of the firm’s stock in a transaction that occurred on Thursday, June 15th. The shares were sold at an average price of $120.18, for a total value of $575,061.30. Following the completion of the transaction, the insider now directly owns 4,004 shares of the company’s stock, valued at $481,200.72. The disclosure for this sale can be found here. Insiders sold a total of 253,761 shares of company stock valued at $33,792,445 over the last ninety days. 0.95% of the stock is currently owned by company insiders.
Celgene Corporation Company Profile
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.